Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Ursula, Ehmer"'
Autor:
Najib Ben Khaled, Marie Möller, Leonie S. Jochheim, Catherine Leyh, Ursula Ehmer, Katrin Böttcher, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Alexander Weich, Hans Benno Leicht, Valentina Zarka, Liangtao Ye, Julia Schneider, Ignazio Piseddu, Osman Öcal, Monika Rau, Friedrich Sinner, Marino Venerito, Simon Johannes Gairing, Friedrich Förster, Julia Mayerle, Enrico N. De Toni, Andreas Geier, Florian P. Reiter
Publikováno v:
JHEP Reports, Vol 6, Iss 6, Pp 101065- (2024)
Background & Aims: Atezolizumab/bevacizumab (atezo/bev) and lenvatinib have demonstrated efficacy as first-line therapies for hepatocellular carcinoma (HCC). However, vascular endothelial growth factor (VEGF) inhibition with these therapies may be as
Externí odkaz:
https://doaj.org/article/8bfa5b4342fd47ce9b2a38f731714629
Autor:
Yuan Guan, Dan Xu, Phillip M. Garfin, Ursula Ehmer, Melissa Hurwitz, Greg Enns, Sara Michie, Manhong Wu, Ming Zheng, Toshihiko Nishimura, Julien Sage, Gary Peltz
Publikováno v:
JCI Insight, Vol 8, Iss 20 (2023)
Externí odkaz:
https://doaj.org/article/c862f874a6f64c1796444bc6e73fbfe5
Autor:
Eunsun Kim, Amanda Lisby, Connie Ma, Nathanael Lo, Ursula Ehmer, Katharina E. Hayer, Emma E. Furth, Patrick Viatour
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-17 (2019)
Aberrant Wnt/b-catenin signaling is thought to be a major driver of hepatocellular carcinoma. Here, the authors show that β-Catenin is predominantly integrated within the AJ complex during the early stages of this cancer and enhance EGFR signaling t
Externí odkaz:
https://doaj.org/article/23d83511c5b14bb7b618f8c1a6766131
Autor:
Michael Wührl, Marc Ringelhan, Ursula Ehmer, Jochen Schneider, Juliane Kager, Tobias Lahmer, Anna Schneider, Wilko Weichert, Carolin Mogler
Publikováno v:
Die Pathologie. 44:53-62
Zusammenfassung Hintergrund Die (transjuguläre) Leberbiopsie stellt einen essenziellen diagnostischen Baustein im Diagnosealgorithmus der unklaren Hepatopathie bzw. des akuten Leberversagens dar. Die Beurteilung und Auswertung erfordert eine eng ver
Autor:
Sabrina Welland, Catherine Leyh, Fabian Finkelmeier, André Jefremow, Kateryna Shmanko, Maria A. Gonzalez-Carmona, Arne Kandulski, Petia Jeliazkova, Jan Best, Thorben W. Fründt, Angela Djanani, Maria Pangerl, Andreas Maieron, Richard Greil, Christina Fricke, Disorn Sookthai, Rainer Günther, Andreas Schmiderer, Henning Wege, Marino Venerito, Ursula Ehmer, Martina Müller, Christian P. Strassburg, Arndt Weinmann, Jürgen Siebler, Oliver Waidmann, Christian M. Lange, Anna Saborowski, Arndt Vogel
Publikováno v:
Liver Cancer, p 1 (2022)
Background Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world patients is insufficiently defined. The purpose of this study was to evaluate the
Externí odkaz:
https://doaj.org/article/8a92700df3fd4606aa03d07ae73baa60
Autor:
Sebastian Schölch, Benedikt Brors, Albrecht Stenzinger, Ursula Ehmer, Ulrich-Frank Pape, Christoph Springfeld, Dirk Jäger, Felix J Hüttner, Andreas Mock, Christoph E Heilig, Simon Kreutzfeldt, Daniel Huebschmann, Christoph Heining, Evelin Schröck, Richard Schlenk, Hanno Glimm, Stefan Fröhling, Peter Horak, Leonidas Apostolidis, Marinela Augustin, Daniela Aust, Irfan Ahmed Bhatti, Johannes Bloehdorn, Cornelia Brendel, Christian Britschgi, Jan Braess, Stefan Burdach, Elena Busch, Jozefina Casuscelli, Alexander Desuki, Thomas Deutsch, Mareike Dietrich, Thomas J Ettrich, Johanna Falkenhorst, Tanja Fehm, Anne Flörcken, Andrea Forschner, Stefan Fuxius, Maria Gonzales-Carmona, Frank Griesinger, Sabine Grill, Stefan Gröschel, Georg Martin Haag, Ulrich Haag, Niels Halama, Holger Hebart, Nina Heidger, Barbara Hermes, Georg Hess, Simone Hettmer, Manuela Hoechstetter, Martin Hoffmann, Anna L Illert, Maximilian Jenzer, Bernd Kasper, Stefan Kasper-Virchow, Thomas Kindler, Ewa Koscielniak, Jan Krönke, Michael Kühn, Volker Kunzmann, Alois Lang, Jonas Leichsenring, Elisabeth Livingstone, Lucia Liotta, Kim Luley, Elisabeth Mack, Uwe M Martens, Klaus Metzeler, Jan Moritz Middeke, Lino Möhrmann, Roopa Jayarama-Naidu, Lukas Perkhofer, Arne Pfeufer, Constantin Pixberg, Michael Quante, Bernhard Rendenbach, Damian Rieke, Christian Rothermundt, Andre Norbert Sagerer, Martin Salzmann, Dieter Saur, Bastian Schilling, Jan Schleicher, Anke Schlenska-Lange, Thomas Schmidt, Sophia Schmitz, Rajiv Shah, Khalid Shoumariyeh, Alexander Siebenhüner, Martin Singh, Jens Siveke, Helen Starke, Sophia Strobel, Veronica Teleanu, Niklas Thon, Sebastian Wagner, Thomas Walle, Benedikt Westphalen, Bettina Whitlock, Eva Winkler, Naita Maren Wirsik, Lena Woydack, Angelika Zabel-du Bois, Stefanie Zschäbitz
Publikováno v:
ESMO Open, Vol 4, Iss 6 (2019)
Objective Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecul
Externí odkaz:
https://doaj.org/article/0122f1ac148444cbaeb951db5af876a5
Autor:
Saumya Manmadhan, Ursula Ehmer
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 7 (2019)
The first description of Hippo signaling in mammals a little more than 10 years ago showed a striking phenotype in the liver, linking the role of this signaling pathway to organ size control and carcinogenesis. Even though Hippo signaling has been ex
Externí odkaz:
https://doaj.org/article/2b5ce4dd300d4239b8201e83ecb2a14a
Autor:
Elnaz Payani, Nikolaus Börner, Dionysios Kolliogiannis, Stefan Brunner, Ingo Klein, Ursula Ehmer, Gerald Denk, Christian M. Lange, Klaudja Ograja, Peter Dietrich, Jens Werner, Markus Guba
Publikováno v:
Langenbeck's Archives of Surgery. 408
Purpose The objective of this work was to uncover inequalities in access to liver transplantation in Bavaria, Germany. Methods For this purpose, the annual transplantation rate per 1 million inhabitants for the respective districts was determined fro
Autor:
Najib Ben Khaled, Max Seidensticker, Jens Ricke, Julia Mayerle, Bettina Oehrle, Daniel Rössler, Daniel Teupser, Ursula Ehmer, Michael Bitzer, Dirk Waldschmidt, Martin Fuchs, Philipp A Reuken, Christian M Lange, Henning Wege, Arne Kandulski, Alexander Dechêne, Marino Venerito, Marie-Luise Berres, Tom Luedde, Ilja Kubisch, Florian P Reiter, Enrico N De Toni
Publikováno v:
Future Oncology. 18:1423-1435
The combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF bevacizumab is the first approved immunotherapeutic regimen for first-line therapy in patients with unresectable hepatocellular carcinoma (HCC), currently approved in more than
Autor:
Thorsten Kaltenbacher, Jessica Löprich, Roman Maresch, Julia Weber, Sebastian Müller, Rupert Oellinger, Nina Groß, Joscha Griger, Niklas de Andrade Krätzig, Petros Avramopoulos, Deepak Ramanujam, Sabine Brummer, Sebastian A. Widholz, Stefanie Bärthel, Chiara Falcomatà, Anja Pfaus, Ahmed Alnatsha, Julia Mayerle, Marc Schmidt-Supprian, Maximilian Reichert, Günter Schneider, Ursula Ehmer, Christian J. Braun, Dieter Saur, Stefan Engelhardt, Roland Rad
Publikováno v:
Nature Protocols. 17:1142-1188
Genetically engineered mouse models (GEMMs) transformed the study of organismal disease phenotypes but are limited by their lengthy generation in embryonic stem cells. Here, we describe methods for rapid and scalable genome engineering in somatic cel